The strategic use of patient discount coupons by pharmaceutical companies represents a sophisticated market manipulation that ultimately drives up healthcare costs for everyone. This economic analysis reveals how biologic drug manufacturers weaponize seemingly patient-friendly coupon programs to maintain monopolistic pricing power when facing competition from cheaper biosimilar alternatives. The research examined 43,088 commercially insured patients across 47 biologic products, focusing on manufacturer coupon deployment patterns between 2017-2019. The analysis identified a clear pattern where companies strategically increase coupon availability and generosity for reformulated 'line extension' drugs when their original biologics face biosimilar competition after 12 years of market exclusivity. This practice, known as product hopping, allows manufacturers to shepherd patients toward newer formulations that reset patent protection timelines. The coupon strategy creates an artificial price advantage that undermines the competitive pressure biosimilars should exert on the market. While patients benefit from reduced immediate out-of-pocket costs, the broader healthcare system absorbs inflated insurance premiums and plan costs. This represents a sophisticated form of evergreening—the practice of extending patent monopolies through minor modifications rather than genuine innovation. The findings illuminate how patient assistance programs can paradoxically harm long-term affordability by preventing natural market competition. For health-conscious adults navigating prescription costs, understanding these market dynamics becomes crucial for making informed decisions about treatment options and recognizing when apparent savings may contribute to systemic healthcare inflation.